Literature DB >> 11058631

Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

A J Kumar1, N E Leeds, G N Fuller, P Van Tassel, M H Maor, R E Sawaya, V A Levin.   

Abstract

PURPOSE: To describe both the common and less frequently encountered magnetic resonance (MR) imaging features of radiation therapy- and chemotherapy-induced brain injury, with particular emphasis on radiation necrosis.
MATERIALS AND METHODS: A cohort of 148 adult patients underwent surgical resection of malignant brain (glial) tumors and were subsequently entered into a research protocol that consisted of accelerated radiation therapy with carboplatin followed by chemotherapy with procarbazine, lomustine, and vincristine. Patients typically underwent sequential MR imaging at 6-8-week intervals during the 1st year and at 3-6-month intervals during subsequent years. In all patients, histopathologic confirmation of lesion composition was performed by board-certified neuropathologists.
RESULTS: The patients exhibited different types of MR imaging-detected abnormalities of the brain: pure radiation necrosis in 20 patients, a mixture of predominantly radiation necrosis with limited recurrent and/or residual tumor (less than 20% of resected tissue) in 16 patients, radiation necrosis of the cranial nerves and/or their pathways in two patients, radiation-induced enhancement of the white matter in 52 patients, and radiation-induced enhancement of the cortex in nine patients.
CONCLUSION: The frequent diagnostic dilemma of recurrent neoplasm versus radiation necrosis is addressed in this study through a description of the varying spatial and temporal patterns of radiation necrosis at MR imaging.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058631     DOI: 10.1148/radiology.217.2.r00nv36377

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  206 in total

1.  Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Authors:  John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari
Journal:  CNS Oncol       Date:  2014

2.  Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.

Authors:  Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2011-12-06       Impact factor: 12.300

3.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

4.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

Review 5.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

Review 6.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

7.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

Review 8.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

Review 9.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

10.  High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.

Authors:  John M Watkins; David T Marshall; Sunil Patel; Pierre Giglio; Amy E Herrin; Elizabeth Garrett-Mayer; Joseph M Jenrette
Journal:  J Neurooncol       Date:  2009-01-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.